The litigation alleges that Replimune executives misled shareholders by failing to disclose critical regulatory hurdles during the specified period. Specifically, the complaint claims the company did not address FDA concerns regarding study designs for its Biologics License Application (BLA). Furthermore, the lawsuit asserts that data submitted from an unplanned analysis of the RP1-104 study relied on only 40 patients—a fraction of the 400-patient enrollment target—leaving the company’s clinical programs vulnerable to rejection.

Shareholders seeking to participate or serve as lead plaintiff must contact the firm by the October deadline. While the case currently awaits class certification, investors who purchased shares during the window remain eligible to participate or retain alternative counsel. Glancy Prongay Wolke & Rotter LLP, based in Los Angeles, is managing the filing, citing its prior track record in investor recovery litigation as the basis for representing the affected class.